FCN-647

N/A

Report date: 2024/02/28 11:34:10
NME

Base Information

Drug NameFCN-647
Drug Alias NameFCN-647
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLymphoma, B-CellLymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFochon Pharmaceuticals Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFochon Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsLymphoma

Other Information

ATC CodeN/A
Related LinksN/A